Gefapixant (DrugBank: Gefapixant)
2 diseases| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 85 | Idiopathic interstitial pneumonia | 2 |
| 226 | Interstitial cystitis with Hunners ulcer | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02502097 (ClinicalTrials.gov) | August 26, 2015 | 16/7/2015 | A Study of Gefapixant (AF-219/MK-7264) in Participants With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough (MK-7264-016) | A Randomized Placebo-Controlled Study to Assess the Efficacy and Safety of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) With Persistent Cough | Idiopathic Pulmonary Fibrosis;Cough | Drug: Gefapixant;Other: Placebo | Afferent Pharmaceuticals, Inc. | NULL | Completed | 40 Years | N/A | All | 51 | Phase 2 | United States |
| 2 | NCT02477709 (ClinicalTrials.gov) | July 20, 2015 | 17/6/2015 | A Study to Assess the Tolerability of a Single Dose of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF) | A Study to Assess the Tolerability of a Single Dose of AF-219, a P2X3 Receptor Antagonist, in Subjects With Idiopathic Pulmonary Fibrosis (IPF) | Idiopathic Pulmonary Fibrosis | Drug: Gefapixant | Afferent Pharmaceuticals, Inc. | NULL | Completed | 40 Years | N/A | All | 6 | Phase 2 | United States |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01569438 (ClinicalTrials.gov) | April 13, 2012 | 30/3/2012 | The Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Female Participants With Interstitial Cystitis /Bladder Pain Syndrome (MK-7264-005) | A Four-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety and Efficacy of AF-219 in Female Subjects With Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS) | Bladder Pain Syndrome | Drug: Gefapixant;Drug: Placebo | Afferent Pharmaceuticals, Inc. | NULL | Terminated | 18 Years | 80 Years | Female | 107 | Phase 2 | United States |